TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35552050

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 1866

Group type: COMPARATOR
Intervention: Usual care nutrition
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: NRS 2002
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: SGA
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: MNA
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: SNAQ
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: MUST
Number of subjects: 1866
Study: 34057649

Group type: EXPERIMENTAL
Intervention: smartphone-based pain management application
Number of subjects: 192

Group type: COMPARATOR
Intervention: face-to-face pain management program
Number of subjects: 192
Study: 32438250

Group type: EXPERIMENTAL
Intervention: Immunocastration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pelvic suspension
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wet ageing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (Intact males)
Number of subjects: 10
Study: 34238835

Group type: EXPERIMENTAL
Intervention: Preference-sensitive instrument for shared decision-making
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Shared Decision-Making Questionnaire
Number of subjects: 46

Group type: COMPARATOR
Intervention: Gynecologists' application of the instrument
Number of subjects: 46
Study: 33196101

Group type: EXPERIMENTAL
Intervention: Dose reduction strategy for adalimumab, etanercept and ustekinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 33172225

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Group 1)
Number of subjects: 60
Study: 32061400

Group type: EXPERIMENTAL
Intervention: 125 mg methylprednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 34078432

Group type: EXPERIMENTAL
Intervention: Two-hour educational programme in situation awareness
Number of subjects: 20

Group type: COMPARATOR
Intervention: Training without education in situation awareness (Control)
Number of subjects: 20
Study: 32221496

Group type: EXPERIMENTAL
Intervention: Audio-visual presentation and written information in the format of mind maps
Number of subjects: 93

Group type: COMPARATOR
Intervention: Audio-visual presentation and written information in the format of leaflets from British Orthodontic Society
Number of subjects: 93

Group type: COMPARATOR
Intervention: Audio-visual presentation and written information in the format of generic mind map
Number of subjects: 93
Study: 35428982

Group type: EXPERIMENTAL
Intervention: ACE‐083 240 mg/muscle injected bilaterally every 3 weeks in the biceps brachii (BB) muscles
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ACE‐083 240 mg/muscle injected bilaterally every 3 weeks in the tibialis anterior (TA) muscles
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo injected bilaterally every 3 weeks in the biceps brachii (BB) muscles
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo injected bilaterally every 3 weeks in the tibialis anterior (TA) muscles
Number of subjects: 58
Study: 33769358

Group type: EXPERIMENTAL
Intervention: Early phacoemulsification
Number of subjects: 62

Group type: COMPARATOR
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 62
Study: 32337698

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mosapride control (MC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham EA & Mosapride (MS)
Number of subjects: 96
Study: 35057416

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (SP) supplementation (50 mg·kg−1 of FFM/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (SP) supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 32291309

Group type: EXPERIMENTAL
Intervention: HFNC at 60 L/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HFNC at 40 L/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline (no therapy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HFNC (20, 40, and 60 L/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional nasal prongs at 5 L/min
Number of subjects: 10
Study: 35326369

Group type: EXPERIMENTAL
Intervention: TAU + MCT
Number of subjects: 100

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 100
Study: 33925633

Group type: EXPERIMENTAL
Intervention: 5 billion CFU of a multi-strain probiotic
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 34496930

Group type: EXPERIMENTAL
Intervention: Teletrial model for recruitment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional recruitment methods (not explicitly mentioned but implied as control)
Number of subjects: 0
Study: 32415981

Group type: EXPERIMENTAL
Intervention: Recovery from hyponatraemia
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Increase in serum sodium level at day 4
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Increase in serum sodium level at day 7
Number of subjects: 118

Group type: COMPARATOR
Intervention: Baseline hyponatraemia
Number of subjects: 118

Group type: COMPARATOR
Intervention: Baseline serum sodium level
Number of subjects: 118
Study: 35587462

Group type: EXPERIMENTAL
Intervention: Video with male narrator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video with female narrator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcript of the video
Number of subjects: 0

Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 0
Study: 34019483

Group type: EXPERIMENTAL
Intervention: CAU plus one dose of 0.1 mg/kg oral ondansetron
Number of subjects: 194

Group type: COMPARATOR
Intervention: CAU (oral rehydration therapy)
Number of subjects: 194
Study: 34941339

Group type: EXPERIMENTAL
Intervention: Life Review Therapy (LRT-HS), approximately 20 sessions including structured life review, narrative exposure, cognitive and behavioral elements.
Number of subjects: 2
Study: 34231281

Group type: EXPERIMENTAL
Intervention: EscharEx
Number of subjects: 73

Group type: COMPARATOR
Intervention: gel vehicle
Number of subjects: 73
Study: 35410322

Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paracetamol treatment
Number of subjects: 20
Study: 34014688

Group type: EXPERIMENTAL
Intervention: Motivational enhancement and cognitive behavioral therapies plus adjunctive pharmacotherapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Motivational enhancement and cognitive behavioral therapies plus placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Time with cannabis‐using friends and siblings
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Time with parents or non‐using siblings
Number of subjects: 65
Study: 32057088

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study: 35782469

Group type: EXPERIMENTAL
Intervention: Vaccine hesitancy due to misinformation, conspiracies, myths, and rumors about side effects of vaccination.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Digital media as a primary source of information regarding vaccination.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Healthcare system uncertainty.
Number of subjects: 17
Study: 32397850

Group type: EXPERIMENTAL
Intervention: BBR plus bezafibrate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BBR
Number of subjects: 36
Study: 32997900

Group type: EXPERIMENTAL
Intervention: Faster R‐CNN nomogram for predicting metastatic LN status
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Faster R‐CNN nomogram for predicting LN metastasis degree
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Calibration plots and decision curve analyses
Number of subjects: 545
Study: 34905152

Group type: EXPERIMENTAL
Intervention: 2D‐STE analysis in DMD group
Number of subjects: 25
Study: 32513144

Group type: EXPERIMENTAL
Intervention: Radiomic nomogram incorporating radiomic signature and conventional CT signs
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Radiomic signature consisting of five radiomic features
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Conventional CT signs
Number of subjects: 210
Study: 34056868

Group type: EXPERIMENTAL
Intervention: MDASS (Mindsets of Depression, Anxiety, and Stress Scale)
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: MDASS with reversed items
Number of subjects: 1735
Study: 32898050

Group type: EXPERIMENTAL
Intervention: Strenuous exercise (≥90 minutes per week)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Less active (exercised less than 90 minutes per week)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Comparison of activity levels
Number of subjects: 351
Study: 32049857

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (14 sessions over 2 weeks) with anti-depressant treatment
Number of subjects: 176

Group type: COMPARATOR
Intervention: Wait-list control group receiving only anti-depressant treatment
Number of subjects: 176
Study: 35672690

Group type: EXPERIMENTAL
Intervention: liposomal MTP-PE alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: liposomal MTP-PE in combination with ifosfamide
Number of subjects: 8
Study: 32732229

Group type: EXPERIMENTAL
Intervention: Thermal disinfection at 70°C and 50% relative humidity for 60 minutes
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Thermal disinfection at 70°C and 50% relative humidity
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Multiple cycles of thermal disinfection
Number of subjects: 4

Group type: COMPARATOR
Intervention: Untreated inoculated control masks
Number of subjects: 4
Study: 35548071

Group type: EXPERIMENTAL
Intervention: Parent-child relationship score
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Parental Stress Scale
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Perceived Parental Aggression Scale
Number of subjects: 485
Study: 34070315

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 54
Study: 33033844

Group type: EXPERIMENTAL
Intervention: New face mask
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional face mask
Number of subjects: 10
Study: 36253042

Group type: EXPERIMENTAL
Intervention: Functional relaxation (FR) therapy, implemented as group therapy, 12 sessions led by a certified physiotherapist once a week.
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo relaxation intervention for the same duration as the FR therapy.
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Functional relaxation (FR) therapy
Number of subjects: 270
Study: 32030417

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 4300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4300
Study: 35000236

Group type: EXPERIMENTAL
Intervention: ritlecitinib
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: brepocitinib
Number of subjects: 142

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: AASIS and SALT scores correlation
Number of subjects: 142
Study: 33998296

Group type: EXPERIMENTAL
Intervention: Gamification with collaboration
Number of subjects: 553

Group type: COMPARATOR
Intervention: Control
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Gamification with support
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Gamification with competition
Number of subjects: 553
Study: 35679461

Group type: EXPERIMENTAL
Intervention: Traditional endodontic access cavity design
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite solution (5.25%)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Gel-based formulation of sodium hypochlorite
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 148

Group type: COMPARATOR
Intervention: Conservative endodontic access cavity design
Number of subjects: 148
Study: 35795100

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block (PVB) followed by sufentanil patient-controlled intravenous analgesia (PCIA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sufentanil patient-controlled intravenous analgesia (PCIA) only
Number of subjects: 80
Study: 32350909

Group type: EXPERIMENTAL
Intervention: ixazomib plus lenalidomide-dexamethasone (IRd)
Number of subjects: 722

Group type: COMPARATOR
Intervention: placebo plus lenalidomide-dexamethasone (placebo-Rd)
Number of subjects: 722
Study: 35251438

Group type: EXPERIMENTAL
Intervention: Acupuncture (10 weekly sessions of manual Acupuncture)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Acupuncture (10 weekly sessions of Sham Acupuncture)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-List Control (10 weeks on a Wait-List)
Number of subjects: 0
Study: 34157053

Group type: EXPERIMENTAL
Intervention: DSEQ (Digital-Screen Exposure Questionnaire)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: DSEQ
Number of subjects: 400
Study: 34999679

Group type: EXPERIMENTAL
Intervention: Probiotics (ORS, zinc plus probiotics)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo (ORS, zinc plus placebo)
Number of subjects: 500
Study: 32094013

Group type: EXPERIMENTAL
Intervention: Direct Superior (DS) approach
Number of subjects: 5341

Group type: EXPERIMENTAL
Intervention: Direct Anterior (DA) approach
Number of subjects: 5341

Group type: COMPARATOR
Intervention: Posterolateral (PL) approach
Number of subjects: 5341
Study: 35220180

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pectoserratus Plane Block (PSPB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (received intravenous tenoxicam and paracetamol, with morphine via patient‐controlled analgesia)
Number of subjects: 90
Study: 32000786

Group type: EXPERIMENTAL
Intervention: House characteristics (presence of screens on windows, possession of LLINs)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: House characteristics (opened eaves, high number of windows, presence of holes in walls, living close to breeding sites)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Anopheles gambiae s.l. tested by ELISA
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: House characteristics
Number of subjects: 467
Study: 33120756

Group type: EXPERIMENTAL
Intervention: Acupuncture Deqi group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Acupuncture without Deqi group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 300
Study: 36273360

Group type: EXPERIMENTAL
Intervention: ECP + cataract surgery (Group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECP + cataract surgery + iStent inject (Group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 33675343

Group type: COMPARATOR
Intervention: Non-interesterified fat (non-IE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Interesterified fat (IE)
Number of subjects: 20
Study: 32141365

Group type: EXPERIMENTAL
Intervention: Passive music therapy during catheter placement and post-procedure (30-45 min during placement, twice a day for 30 min until discharge)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 304
Study: 35084480

Group type: EXPERIMENTAL
Intervention: Plinabulin, 40 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Pegfilgrastim, 6 mg
Number of subjects: 105
Study: 33731209

Group type: EXPERIMENTAL
Intervention: GV-971 (900 mg)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study: 36088650

Group type: COMPARATOR
Intervention: GSK2831781 450 mg IV
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK2831781 150 mg SC
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK2831781 450 mg SC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo SC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK2831781 (IV and SC)
Number of subjects: 0
Study: 32457083

Group type: EXPERIMENTAL
Intervention: Encapsulated FMT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33453140

Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study: 32088993

Group type: EXPERIMENTAL
Intervention: WM-targeted cognitive remediation program (25 sessions of 30-40 minutes over 5 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: WM-targeted cognitive remediation program
Number of subjects: 28
Study: 33485464

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg intravenously once every 2 weeks) plus ipilimumab (1 mg/kg intravenously once every 6 weeks) for up to 2 years
Number of subjects: 605

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed [500 mg/m2 intravenously] plus cisplatin [75 mg/m2 intravenously] or carboplatin [area under the concentration‐time curve 5 mg/mL per min intravenously]) once every 3 weeks for up to six cycles
Number of subjects: 605
Study: 32811682

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PARP inhibitors overall
Number of subjects: 47
Study: 34382454

Group type: EXPERIMENTAL
Intervention: Digital disease management platform (hybrid mHealth model integrating remote patient monitoring and applied health technology)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 45
Study: 33128473

Group type: EXPERIMENTAL
Intervention: 1% LT-BOL cream
Number of subjects: 21
Study: 36220980

Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (DA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: recombinant human erythropoietin (rHuEPO)
Number of subjects: 50
Study: 33704494

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: High diastolic blood pressure (DBP)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (SBP)
Number of subjects: 1320
Study: 35923425

Group type: EXPERIMENTAL
Intervention: B-EV71 vaccine (Older-B group)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: C-EV71 vaccine (Older-C group)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: B-EV71 vaccine (Younger-B group)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Older-B group
Number of subjects: 1600
Study: 32790955

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physiotherapy (CPT)
Number of subjects: 0
Study: 36058697

Group type: EXPERIMENTAL
Intervention: Lower abdomen group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lateral abdomen group
Number of subjects: 60
Study: 34571023

Group type: EXPERIMENTAL
Intervention: CNS stimulants
Number of subjects: 230
Study: 36176768

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHG) - 4 × 2 min at 30% of maximal voluntary contraction (MVC) with 1 min rest between sets, unilateral
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham group - protocol at 0.3% of MVC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 0
Study: 33037632

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 743

Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 743
Study: 34478604

Group type: EXPERIMENTAL
Intervention: Retropubic tape (TVT, GYNECARE™)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Transobturator tape (TOT, MONARC™)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both TVT and TOT
Number of subjects: 180
Study: 32342857

Group type: EXPERIMENTAL
Intervention: 30 ml/kg/day feed increments
Number of subjects: 2804

Group type: COMPARATOR
Intervention: 18 ml/kg/day feed increments
Number of subjects: 2804
Study: 35403244

Group type: EXPERIMENTAL
Intervention: SMOF Lipid Emulsion (SMOF‐LE)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Non-SMOF Lipid Emulsion (non‐SMOF‐LE)
Number of subjects: 528
Study: 32210340

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 109
Study: 35299968

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, Bifidobacterium animalis subsp. lactis CP-9) administered daily for 6 months along with regular insulin therapy.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (insulin therapy without probiotics).
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Probiotics intervention.
Number of subjects: 56
Study: 33300212

Group type: EXPERIMENTAL
Intervention: semi‐elevated right lateral position
Number of subjects: 34

Group type: COMPARATOR
Intervention: semi‐elevated supine position
Number of subjects: 34
Study: 33235307

Group type: EXPERIMENTAL
Intervention: Vype ePen3 with greater aerosol mass delivery
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Protonated nicotine (18 mg/mL, medium protonation) e-liquid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nicotine benzoate formulation (30 mg/mL nicotine, high protonation)
Number of subjects: 24
Study: 33704372

Group type: EXPERIMENTAL
Intervention: MRCIP (Mendelian randomization method)
Number of subjects: 0
Study: 32166538

Group type: EXPERIMENTAL
Intervention: Netarsudil/Latanoprost FDC (0.02%/0.005%)
Number of subjects: 1468

Group type: COMPARATOR
Intervention: Netarsudil (0.02%)
Number of subjects: 1468

Group type: COMPARATOR
Intervention: Latanoprost (0.005%)
Number of subjects: 1468
Study: 36226244

Group type: EXPERIMENTAL
Intervention: MTX and LEF combination therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: MTX only (Control)
Number of subjects: 120